Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Creative Medical Technology Holdings Inc (NQ: CELZ )

4.820 -0.010 (-0.21%)
Streaming Delayed Price Updated: 9:47 AM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Creative Medical Technology Holdings Inc

< Previous 1 2 3 4 5 Next >
Creative Medical Technology Holdings Provides Corporate Update
From Creative Medical Technology Holdings, Inc.
Via Business Wire
Market Momentum: NASDAQ SmallCaps Sparking Waves in March 2024: CELZ, DYAI, GROM, VTAK, BREA
Via AB Newswire
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why Is Diabetes Focused Creative Medical Stock Surging On Thursday?
FDA approval under expanded access for Creative Medical. CELZ-201, a pioneering cell-based program, targets abnormal glucose tolerance to prevent Type 1 diabetes. 
Via Benzinga
Exposures Product Safety
What Is Allogeneic Cell Therapy, And What’s Driving This Market’s 25%+ Annual Global Growth?
Via ACCESSWIRE
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of HighPeak Energy, Inc. (NASDAQ: HPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
From Creative Medical Technology Holdings, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
From Creative Medical Technology Holdings, Inc.
Via Business Wire
Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain
Via ACCESSWIRE
Creative Medical Technology Holdings (NASDAQ: CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem™ For Addressing Chronic Lower Back Pain
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company has received clearance from the FDA to conduct a phase 1/2 clinical trial using their innovative StemSpine® treatment... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another busy day of trading as we go over the biggest pre-market stock movers worth watching on Tuesday morning! 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the week with a breakdown of the biggest pre-market stock movers that investors need to know about for Monday! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Mainz Biomed Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares rose 38.7% to $0.1713 in pre-market trading. Shares of Avalo Therapeutics jumped over 45% on Tuesday after the company agreed to divest AVTX-800... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we check out all the shares worth watching on Wednesday! 
Via InvestorPlace
What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?
Biotechnology company Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) seems to be witnessing success in the allogeneic cell therapy market.  
Via Benzinga
Why EVgo Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Why Rover Group Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares surged 52.1% to $0.1049 in pre-market trading. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another breakdown of the biggest pre-market stock movers as we check out all of the latest news for Wednesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting off the day with a breakdown of all the biggest pre-market stock movers traders need to know about on Friday! 
Via InvestorPlace
Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update
Via ACCESSWIRE
The Immunotherapy Market Is Expected To Surpass $351.56 Billion By 2030 – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) Is Contributing to This Growth
Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat various diseases. While historically this... 
Via Benzinga
Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) Reports Advancements In Its Immunotherapy Programs And Confidence In Its Financial Position In Corporate Update
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology") (NASDAQ: CELZ) recently released an update on their scientific pipeline and financial standing going into Q3 2023. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.